Trial Profile
Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasiprotimut T (Primary) ; Keyhole limpet haemocyanin
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms BiovaxID
- Sponsors Biovest International
- 02 Feb 2012 Additional lead trial investigator (Carlos F Santos) identified as reported by ClinicalTrials.gov.
- 02 Feb 2012 Additional lead trial investigator (Carlos F Santos) identified as reported by ClinicalTrials.gov.
- 02 Feb 2012 Additional lead trial investigator (Carlos F Santos) identified as reported by ClinicalTrials.gov.